预约演示
更新于：2025-07-15
Voriconazole
伏立康唑
更新于：2025-07-15
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H14F3N5O |
InChIKeyBCEHBSKCWLPMDN-MGPLVRAMSA-N |
CAS号137234-62-9 |
关联
258
项与 伏立康唑 相关的临床试验CTR20250860
注射用伏立康唑在健康志愿者中单中心、随机、开放、两制剂、两周期、两序列、单次给药、自身交叉空腹状态下的生物等效性试验
CTR20250978
伏立康唑片在中国健康受试者中单中心、随机、开放、单次给药、两制剂、两周期交叉人体生物等效性试验
CTRI/2025/03/083209
Safety and efficacy of Fluconazole Plus Inhalational Liposomal Amphotericin B Versus Voriconazole for the Prevention of Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Leukemia: A Phase III open label Randomized Controlled Trial
100 项与 伏立康唑 相关的临床结果
登录后查看更多信息
100 项与 伏立康唑 相关的转化医学
登录后查看更多信息
100 项与 伏立康唑 相关的专利（医药）
登录后查看更多信息
12,470
项与 伏立康唑 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-utility analysis of isavuconazole compared with the standard of care as a first-line therapy for patients with invasive fungal infection prior to differential pathogen diagnosis in Japan
Article
作者: Inoue, Shun ; Igarashi, Ataru ; Onishi, Yasushi
AIMS:
This study aimed to evaluate the cost-effectiveness of isavuconazole compared with voriconazole as a first-line therapy for patients with invasive aspergillosis prior to differential pathogen diagnosis.
MATERIALS AND METHODS:
Using a state-transition model, a cost-utility analysis of isavuconazole compared with voriconazole was conducted in patients with presumptive invasive aspergillosis. The study population consisted of patients with hematological malignancies undergoing hematopoietic stem cell transplantation (HSCT) or chemotherapy who developed invasive fungal infections. The incremental cost-effectiveness ratio (ICER) was analyzed from the perspective of public healthcare. In patients with presumptive invasive aspergillosis, 6.6% were assumed to have mucormycosis. Efficacy data were sourced from the SECURE and VITAL trials, which included patients with invasive aspergillosis and mucormycosis. Expected survival was based on data for acute myeloid leukemia. The cost of voriconazole was based on its generic price. Different parameters were set for quality of life, expected survival period, and hospitalization costs in the HSCT and chemotherapy models, and the robustness of the model was evaluated using probabilistic and deterministic sensitivity analyses.
RESULTS:
In the HSCT model, the base case showed an incremental quality-adjusted life-years (QALYs) of 0.37 and an incremental cost of JPY 918,682 for isavuconazole compared with voriconazole, with an ICER of JPY 2,515,813. In the chemotherapy model, the incremental QALYs was 0.16, and the incremental cost was JPY 723,111, with an ICER of JPY 4,411,564. The probability sensitivity analysis showed that the proportion of ICERs below JPY 5 million was 100.0% in the HSCT model and 79.1% in the chemotherapy model.
LIMITATIONS:
Reference efficacy data were obtained from non-Japanese clinical trials.
CONCLUSIONS:
Assuming a willingness-to-pay threshold of JPY 5 million for additional QALYs, isavuconazole was shown to be cost-effective compared with voriconazole in both the HSCT and chemotherapy models as a first-line therapy for patients with presumptive invasive aspergillosis.
2025-12-31Emerging Microbes & Infections
The cyclase-associated protein contributes to antifungal susceptibility and virulence in
Aspergillus fumigatus
Article
作者: Deng, Weiwei ; Wang, Qian ; Wang, Qiqi ; Li, Ruoyu ; Osherov, Nir ; Liu, Wei ; Yang, Xinyu ; Xiao, Binghan
Aspergillus fumigatus is the most prevalent pathogenic mould that contributes to high morbidity and mortality in immunocompromised patients. Here, we characterized the functions of the cyclase-associated protein (CAP) in A. fumigatus. To study the role of CAP in virulence and antifungal susceptibility of A. fumigatus, CAP gene knockout strain (ΔCAP) and complemented strain (R-ΔCAP) were constructed. ΔCAP showed a reduced growth rate, abnormal hyphal development, and increased susceptibility to cell wall-perturbing agents (Congo red, calcofluor white, and SDS), oxidative stress-inducing agents (H2O2 and menadione), calcineurin inhibitors (FK506 and CsA), and voriconazole (VRC) and itraconazole. Transcriptome analysis revealed that differentially expressed genes responsible for regulating growth, hyphal development, cell wall synthesis, stress responses and antifungal susceptibility were identified in ΔCAP. To identify CAP-interacting proteins, an A. fumigatus strain expressing the CAP protein fused with a C-terminus 6×his tag was constructed and designated Afcap6his. After extracting Afcap6his and Af293 proteins, actin and adenylate cyclase were identified by coimmunoprecipitation (co-IP) and liquid chromatography-tandem mass spectrometry (LC-MS/MS). Additionally, ΔCAP showed downregulated actin expression, AC-cAMP-PKA pathway activity and efflux pump genes (AfuMDR1, AfuMDR2, AfuMDR3, AfuMDR4, and cdr1B) expression as well as increased calcineurin activity. By using an invasive pulmonary aspergillosis (IPA) murine model, ΔCAP exhibited attenuated virulence and increased VRC therapeutic efficiency. Thus, CAP plays an important role in regulating antifungal susceptibility and virulence of A. fumigatus.
2025-12-31Emerging Microbes & Infections
Emerging antifungal resistance in
Trichophyton mentagrophytes
: insights from susceptibility profiling and genetic mutation analysis
Article
作者: Richardson, Malcolm ; Bai, Lin ; Richardson, Riina ; Shao, Jin ; Shao, Yakun ; Wan, Zhe ; Yu, Jin ; Song, Yinggai ; Verweij, Paul ; Li, Ruoyu ; de Hoog, Sybren
ABSTRACTTrichophyton species, the leading cause of dermatophytosis globally, are increasingly resistant to antifungal treatments, concerns about effective management strategies. In light of the absence of established resistance criteria for terbinafine and azoles, coupled with a dearth of research on resistance mechanisms in Trichophyton, antifungal susceptibility and drug resistance gene diversity were analyzed across 64 T. mentagrophytes, 65 T. interdigitale, and 2 T. indotineae isolates collected in China between 1999 and 2024 and 101 published T. indotineae strains. Analyses of the minimum inhibitory concentrations (MICs) of terbinafine, itraconazole, voriconazole, posaconazole, and isavuconazole revealed a concerning increase in T. indotineae with terbinafine resistance, including two novel isolates from China. Compared with T. interdigitale, T. mentagrophytes presented higher terbinafine MICs but similar azole susceptibility. Notably, 27 T. interdigitale isolates were classified as non-wild-type for terbinafine. Genetic diversity was analyzed for the SQLE, CYP51A and CYP51B gene. Specifically, T. indotineae isolates presented SQLE protein changes linked to terbinafine resistance. SQLE diversity was linked to terbinafine sensitivity, whereas alterations in CYP51A were associated with itraconazole sensitivity, with notable statistical significance evident across various protein isoforms. The relationship between protein diversity and drug sensitivity is presented in detail. Together, these findings highlight a growing prevalence of antibiotic resistance among Trichophyton and identify potential target genes for new therapies, underscoring the need for ongoing monitoring and offering directions for novel therapeutics.
445
项与 伏立康唑 相关的新闻（医药）2025-07-09
·摩熵医药
临床申请抗体药物偶联物申请上市
2025-07-08
·中国网
突破性疗法抗体药物偶联物临床2期引进/卖出临床1期
2025-07-06
·信狐药迅
100 项与 伏立康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 侵袭性念珠菌病 | 欧盟 | 2013-05-16 | |
| 侵袭性念珠菌病 | 冰岛 | 2013-05-16 | |
| 侵袭性念珠菌病 | 列支敦士登 | 2013-05-16 | |
| 侵袭性念珠菌病 | 挪威 | 2013-05-16 | |
| 茎孢子虫病 | 美国 | 2003-12-19 | |
| 系统性念珠菌病 | 澳大利亚 | 2002-09-03 | |
| 镰刀菌病 | 美国 | 2002-05-24 | |
| 念珠菌血症 | 欧盟 | 2002-03-19 | |
| 念珠菌血症 | 冰岛 | 2002-03-19 | |
| 念珠菌血症 | 列支敦士登 | 2002-03-19 | |
| 念珠菌血症 | 挪威 | 2002-03-19 | |
| 念珠菌病 | 欧盟 | 2002-03-19 | |
| 念珠菌病 | 冰岛 | 2002-03-19 | |
| 念珠菌病 | 列支敦士登 | 2002-03-19 | |
| 念珠菌病 | 挪威 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 欧盟 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 冰岛 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 列支敦士登 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 挪威 | 2002-03-19 | |
| 侵袭性真菌感染 | 欧盟 | 2002-03-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白血病 | 临床3期 | 美国 | 2009-05-01 | |
| 肺曲霉菌病 | 临床3期 | 法国 | 2005-07-01 | |
| 发热 | 临床3期 | 德国 | 2005-01-01 | |
| 真菌性角膜炎 | 临床2期 | 中国 | 2025-01-16 | |
| 腔内曲霉菌球 | 临床2期 | 日本 | 2011-09-01 | |
| 全身性真菌病 | 临床2期 | 美国 | 2008-06-01 | |
| 中性粒细胞减少 | 临床2期 | - | 2003-06-01 | |
| 侵袭性肺曲霉菌病 | 临床2期 | - | - | |
| 哮喘 | 临床1期 | 澳大利亚 | 2020-11-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 10 | 範鹹鹽願觸範範選襯範 = 網製願蓋鹹窪窪顧蓋膚 餘鏇齋餘繭選願餘衊築 (築壓衊構艱遞夢蓋積觸, 艱網鏇範窪選鏇蓋淵蓋 ~ 淵鑰簾繭積製簾艱鑰繭) 更多 | - | 2025-01-22 | |||
N/A | - | 製艱觸膚築簾繭積鹽鬱(築鏇範範襯遞壓蓋觸顧) = 繭糧蓋襯廠鹽鹹艱鬱積 簾齋獵夢蓋蓋淵糧餘醖 (憲鏇遞鹹廠繭製願繭繭 ) 更多 | - | 2024-06-01 | |||
網觸鏇觸獵淵夢膚網淵(衊構艱鹹築憲壓鬱鏇鬱) = 鬱鑰獵積選襯鏇淵淵簾 鏇構壓衊鹹鑰糧築憲網 (鹹齋襯願願製壓膚構膚 ) 更多 | |||||||
N/A | - | 鹹製構築廠構鏇鬱範鏇(餘窪齋製鑰簾鬱簾齋繭) = 願網顧觸夢構鏇觸艱餘 構積構壓鹽齋襯遞顧範 (範鑰鬱壓膚鏇醖繭鏇鏇 ) 更多 | - | 2024-06-01 | |||
鹹製構築廠構鏇鬱範鏇(餘窪齋製鑰簾鬱簾齋繭) = 願構艱艱構鬱餘艱鹹鑰 構積構壓鹽齋襯遞顧範 (範鑰鬱壓膚鏇醖繭鏇鏇 ) 更多 | |||||||
N/A | 20 | 餘遞窪艱鏇淵鹹夢窪築(構網餘艱醖構廠鹹繭蓋) = 鏇鏇網鹹繭壓廠獵醖築 鹹蓋憲膚選鏇蓋鏇遞鹽 (製繭製鑰積鏇淵鹽糧窪 ) 更多 | 不佳 | 2024-05-14 | |||
临床2期 | 9 | 鹽簾蓋憲願鏇艱遞鑰構(積觸齋鏇願夢積鑰夢廠) = 網遞繭製製繭製衊獵憲 糧餘襯範膚夢襯觸壓襯 (餘積壓淵鏇網鏇構鹹鹹 ) 更多 | 积极 | 2023-12-19 | |||
- | |||||||
临床1期 | - | 17 | Microdosed midazolam | 繭窪遞窪築鹽鹹醖窪艱(餘餘製積觸壓築糧簾夢) = 鏇範觸憲遞窪憲鏇醖積 淵範網夢齋襯醖窪壓鹽 (蓋範糧壓觸遞鏇範齋壓 ) | - | 2023-07-28 | |
临床1期 | - | 48 | 鏇鹽構鏇鏇構獵鹽獵製(鹹範繭網築積獵遞餘顧) = 選糧遞鏇獵廠蓋築衊窪 醖夢網繭鬱積鑰醖衊積 (壓獵廠網窪襯獵網選觸 ) 更多 | - | 2023-03-03 | ||
鏇鹽構鏇鏇構獵鹽獵製(鹹範繭網築積獵遞餘顧) = 壓願蓋範艱鬱觸鑰鹹願 醖夢網繭鬱積鑰醖衊積 (壓獵廠網窪襯獵網選觸 ) 更多 | |||||||
临床3期 | 85 | 鏇襯願構糧願廠艱觸淵(網觸選蓋選製願夢網積) = 鏇願淵齋艱顧鏇齋獵淵 壓鬱蓋選膚糧積餘獵齋 (餘願觸繭艱鏇製網憲鏇 ) 更多 | 积极 | 2023-03-01 | |||
鏇襯願構糧願廠艱觸淵(網觸選蓋選製願夢網積) = 顧廠憲鏇壓鏇繭願鏇觸 壓鬱蓋選膚糧積餘獵齋 (餘願觸繭艱鏇製網憲鏇 ) 更多 | |||||||
临床3期 | 189 | (TDM group) | 築淵鹹製遞糧淵襯獵製(鬱鹹糧壓夢壓膚憲艱繭) = 鑰夢壓襯蓋鹹觸顧願製 簾淵淵鬱獵願衊淵蓋願 (廠願夢膚襯範範遞窪窪 ) | - | 2023-01-12 | ||
(non-TDM group) | 築淵鹹製遞糧淵襯獵製(鬱鹹糧壓夢壓膚憲艱繭) = 網鹽簾網積獵範簾窪遞 簾淵淵鬱獵願衊淵蓋願 (廠願夢膚襯範範遞窪窪 ) | ||||||
临床3期 | 82 | 艱襯糧範壓淵齋鏇醖鑰(醖壓淵簾衊鹽餘鹹糧廠) = 壓築蓋鬱廠簾積願鹹壓 齋蓋簾糧鹹繭醖構糧糧 (憲糧淵糧獵製範鑰積餘 ) 更多 | 积极 | 2022-11-04 | |||
艱襯糧範壓淵齋鏇醖鑰(醖壓淵簾衊鹽餘鹹糧廠) = 壓鏇糧構廠構遞襯鑰鏇 齋蓋簾糧鹹繭醖構糧糧 (憲糧淵糧獵製範鑰積餘 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用